27.54
price up icon1.25%   0.34
after-market Dopo l'orario di chiusura: 27.51 -0.03 -0.11%
loading

Royalty Pharma Plc Azioni (RPRX) Dati Finanziari

Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
Data di fine periodo 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31
Durata del periodo 3 mesi 3 mesi 3 mesi 3 mesi 3 mesi
Revenues
4.71%
567.98
596.07 536.31 538.20 683.97
Operating Expenses
3,914%
641.75
-16.83 384.87 289.36 205.00
Interest Income/Expense
6.40%
44.23
47.26 46.03 46.95 46.95
Benefits Costs and Expenses
570.92%
572.25
-121.52 414.24 186.87 174.88
Costs And Expenses
3,914%
641.75
-16.83 384.87 289.36 205.00
Provision For Loan, Lease, And Other Losses
107.34%
0.669
-9.12 29.91 -5.922 7.415
Operating Income/Loss
112.04%
-73.77
612.90 151.44 248.84 478.97
Nonoperating Income/Loss
33.61%
69.50
104.69 -29.36 102.50 30.12
Income/Loss Before Equity Method Investments
98.62%
9.876
717.32 127.30 352.11 474.48
Income/Loss From Equity Method Investments
5,379%
-14.15
0.268 -5.222 -0.77 34.61
Income/Loss From Continuing Operations Before Tax
100.60%
-4.273
717.59 122.08 351.34 509.09
Income Tax Expense/Benefit
-
- - - -
Income/Loss From Continuing Operations After Tax
100.60%
-4.273
717.59 122.08 351.34 509.09
Net Income/Loss
100.60%
-4.273
717.59 122.08 351.34 509.09
Preferred Stock Dividends And Other Adjustments
-
- - - -
Attributable To Noncontrolling Interest
104.05%
-9.051
223.25 49.96 123.71 168.33
Basic Average Shares
80,068%
448.62
-0.561 448.44 450.40 445.61
Diluted Average Shares
32,983%
597.48
-1.817 601.14 605.86 607.25
Basic Earnings Per Share
99.10%
0.01
1.11 0.16 0.51 0.76
Diluted Earnings Per Share
99.09%
0.01
1.10 0.16 0.50 0.76
Common Stock Dividends
5.00%
0.21
0.20 0.20 0.20 0.20
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic
-
- - - -
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):